Global collaborations in ophthalmic therapy are
setting the stage for expansion
InSite Vision develops novel ophthalmic products designed to treat a growing range of common eye problems, including ocular infection, glaucoma, and retinal disease. Our goal is to provide patients and physicians with improved treatment options that help preserve and improve vision worldwide.
Based on our proprietary DuraSite® drug delivery technology, we are creating alternative ocular anti-infective therapies, such as AzaSite®, AzaSite Plus™ and AzaSite Xtra™ with the potential to provide significant advantages currently not available with conventional treatment options. Additionally, AzaSite Otic™ is being developed for ear infections.
AzaSite
AzaSite is designed to be a first-line treatment for bacterial conjunctivitis, a common form of eye infection.
DuraSite Technology
The proven DuraSite drug-delivery system can be customized to deliver a wide variety of novel ocular drug candidates.
Rich Pipeline
The InSite Vision portfolio includes marketed products and products in clinical development.